Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables: 2017-2025

Historic Receivables for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $33.6 million.

  • Puma Biotechnology's Receivables fell 39.42% to $33.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.8 million, marking a year-over-year decrease of 25.72%. This contributed to the annual value of $32.4 million for FY2024, which is 33.55% down from last year.
  • Puma Biotechnology's Receivables amounted to $33.6 million in Q3 2025, which was up 28.49% from $26.1 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Receivables high stood at $55.4 million for Q3 2024, and its period low was $23.8 million during Q3 2021.
  • Its 3-year average for Receivables is $33.5 million, with a median of $31.2 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first surged by 87.88% in 2024, then plummeted by 39.42% in 2025.
  • Over the past 5 years, Puma Biotechnology's Receivables (Quarterly) stood at $32.5 million in 2021, then climbed by 24.05% to $40.4 million in 2022, then increased by 20.74% to $48.7 million in 2023, then plummeted by 33.55% to $32.4 million in 2024, then slumped by 39.42% to $33.6 million in 2025.
  • Its last three reported values are $33.6 million in Q3 2025, $26.1 million for Q2 2025, and $25.7 million during Q1 2025.